Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 602

1.

Identification of a γc Receptor Antagonist that Prevents Reprogramming of Human Tissue-resident Cytotoxic T Cells by IL15 and IL21.

Ciszewski C, Discepolo V, Pacis A, Doerr N, Tastet O, Mayassi T, Maglio M, Basheer A, Al-Mawsawi LQ, Green P, Auricchio R, Troncone R, Waldmann TA, Azimi N, Tagaya Y, Barreiro LB, Jabri B.

Gastroenterology. 2019 Oct 14. pii: S0016-5085(19)41440-6. doi: 10.1053/j.gastro.2019.10.006. [Epub ahead of print]

PMID:
31622625
2.

IL-2 receptors preassemble and signal in the ER/Golgi causing resistance to antiproliferative anti-IL-2Rα therapies.

Volkó J, Kenesei Á, Zhang M, Várnai P, Mocsár G, Petrus MN, Jambrovics K, Balajthy Z, Müller G, Bodnár A, Tóth K, Waldmann TA, Vámosi G.

Proc Natl Acad Sci U S A. 2019 Oct 15;116(42):21120-21130. doi: 10.1073/pnas.1901382116. Epub 2019 Sep 30.

PMID:
31570576
3.

Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade.

Rauch DA, Conlon KC, Janakiram M, Brammer JE, Harding JC, Ye BH, Zang X, Ren X, Olson S, Cheng X, Miljkovic MD, Sundaramoorthi H, Joseph A, Skidmore ZL, Griffith O, Griffith M, Waldmann TA, Ratner L.

Blood. 2019 Oct 24;134(17):1406-1414. doi: 10.1182/blood.2019002038.

PMID:
31467059
4.

Results From a First-in-Human Study of BNZ-1, a Selective Multicytokine Inhibitor Targeting Members of the Common Gamma (γc) Family of Cytokines.

Frohna PA, Ratnayake A, Doerr N, Basheer A, Al-Mawsawi LQ, Kim WJ, Zapata JC, Wu X, Waldmann TA, Azimi N, Tagaya Y.

J Clin Pharmacol. 2019 Aug 29. doi: 10.1002/jcph.1522. [Epub ahead of print]

PMID:
31465127
5.

Clinical trial of a humanized anti-IL-2/IL-15 receptor β chain in HAM/TSP.

Enose-Akahata Y, Oh U, Ohayon J, Billioux BJ, Massoud R, Bryant BR, Vellucci A, Ngouth N, Cortese I, Waldmann TA, Jacobson S.

Ann Clin Transl Neurol. 2019 Aug;6(8):1383-1394. doi: 10.1002/acn3.50820. Epub 2019 Jul 5.

6.

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.

Cooley S, He F, Bachanova V, Vercellotti GM, DeFor TE, Curtsinger JM, Robertson P, Grzywacz B, Conlon KC, Waldmann TA, McKenna DH, Blazar BR, Weisdorf DJ, Miller JS.

Blood Adv. 2019 Jul 9;3(13):1970-1980. doi: 10.1182/bloodadvances.2018028332.

7.

IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.

Conlon KC, Potter EL, Pittaluga S, Lee CR, Miljkovic MD, Fleisher TA, Dubois S, Bryant BR, Petrus M, Perera LP, Hsu J, Figg WD, Peer CJ, Shih JH, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA.

Clin Cancer Res. 2019 Aug 15;25(16):4945-4954. doi: 10.1158/1078-0432.CCR-18-3468. Epub 2019 May 29.

8.

Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.

Gamboa-Cedeño AM, Castillo M, Xiao W, Waldmann TA, Ranuncolo SM.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1437-1448. doi: 10.1007/s00432-019-02909-z. Epub 2019 Apr 2.

PMID:
30941572
9.

Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.

Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, Horwitz S, Fields P, Tanase A, Bumbea H, Cwynarski K, Taylor G, Waldmann TA, Bittencourt A, Marcais A, Suarez F, Sibon D, Phillips A, Lunning M, Farid R, Imaizumi Y, Choi I, Ishida T, Ishitsuka K, Fukushima T, Uchimaru K, Takaori-Kondo A, Tokura Y, Utsunomiya A, Matsuoka M, Tsukasaki K, Watanabe T.

J Clin Oncol. 2019 Mar 10;37(8):677-687. doi: 10.1200/JCO.18.00501. Epub 2019 Jan 18.

10.

Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas.

Roswarski J, Roschewski M, Melani C, Pittaluga S, Lucas A, Steinberg SM, Jaffe ES, Waldmann TA, Wilson WH.

Leuk Lymphoma. 2019 Aug;60(8):2062-2066. doi: 10.1080/10428194.2018.1562184. Epub 2019 Jan 10.

PMID:
30626252
11.

Making discoveries in immunology.

Waldmann TA.

Hum Vaccin Immunother. 2019;15(2):280-282. doi: 10.1080/21645515.2018.1549830. Epub 2019 Jan 4. No abstract available.

PMID:
30481119
12.

Minimum degree of overlap between IL-9R and IL-2R on human T lymphoma cells: A quantitative CLSM and FRET analysis.

Nizsalóczki E, Nagy P, Mocsár G, Szabó Á, Csomós I, Waldmann TA, Vámosi G, Mátyus L, Bodnár A.

Cytometry A. 2018 Nov;93(11):1106-1117. doi: 10.1002/cyto.a.23634. Epub 2018 Oct 31.

13.

IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages.

Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, Sato N, DiLillo DJ, Bamford RN, Ravetch JV, Waldmann TA.

Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10915-E10924. doi: 10.1073/pnas.1811615115. Epub 2018 Oct 29.

14.

IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability.

Wang TT, Yang J, Zhang Y, Zhang M, Dubois S, Conlon KC, Tagaya Y, Hamele CE, Dighe S, Olson TL, Feith DJ, Azimi N, Waldmann TA, Loughran TP Jr.

Leukemia. 2019 May;33(5):1243-1255. doi: 10.1038/s41375-018-0290-y. Epub 2018 Oct 23.

15.

Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma.

Nakagawa M, Shaffer AL 3rd, Ceribelli M, Zhang M, Wright G, Huang DW, Xiao W, Powell J, Petrus MN, Yang Y, Phelan JD, Kohlhammer H, Dubois SP, Yoo HM, Bachy E, Webster DE, Yang Y, Xu W, Yu X, Zhao H, Bryant BR, Shimono J, Ishio T, Maeda M, Green PL, Waldmann TA, Staudt LM.

Cancer Cell. 2018 Aug 13;34(2):286-297.e10. doi: 10.1016/j.ccell.2018.06.014. Epub 2018 Jul 26.

16.

Cytokines in the Treatment of Cancer.

Conlon KC, Miljkovic MD, Waldmann TA.

J Interferon Cytokine Res. 2019 Jan;39(1):6-21. doi: 10.1089/jir.2018.0019. Epub 2018 Jun 11.

PMID:
29889594
17.

Protection by universal influenza vaccine is mediated by memory CD4 T cells.

Valkenburg SA, Li OTW, Li A, Bull M, Waldmann TA, Perera LP, Peiris M, Poon LLM.

Vaccine. 2018 Jul 5;36(29):4198-4206. doi: 10.1016/j.vaccine.2018.06.007. Epub 2018 Jun 7.

PMID:
29887326
18.

Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy.

Ratner L, Waldmann TA, Janakiram M, Brammer JE.

N Engl J Med. 2018 May 17;378(20):1947-1948. doi: 10.1056/NEJMc1803181. No abstract available.

PMID:
29768155
19.

Membrane Potential Distinctly Modulates Mobility and Signaling of IL-2 and IL-15 Receptors in T Cells.

Nagy É, Mocsár G, Sebestyén V, Volkó J, Papp F, Tóth K, Damjanovich S, Panyi G, Waldmann TA, Bodnár A, Vámosi G.

Biophys J. 2018 May 22;114(10):2473-2482. doi: 10.1016/j.bpj.2018.04.038. Epub 2018 May 10.

20.

Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.

Lu L, Zhu F, Zhang M, Li Y, Drennan AC, Kimpara S, Rumball I, Selzer C, Cameron H, Kellicut A, Kelm A, Wang F, Waldmann TA, Rui L.

Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E498-E505. doi: 10.1073/pnas.1715118115. Epub 2018 Jan 2.

21.

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors.

Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC.

Clin Cancer Res. 2018 Apr 1;24(7):1525-1535. doi: 10.1158/1078-0432.CCR-17-2451. Epub 2017 Dec 4.

22.

Cytokines in Cancer Immunotherapy.

Waldmann TA.

Cold Spring Harb Perspect Biol. 2018 Dec 3;10(12). pii: a028472. doi: 10.1101/cshperspect.a028472. Review.

PMID:
29101107
23.

Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.

Roswarski J, Roschewski M, Lucas A, Melani C, Pittaluga S, Jaffe ES, Steinberg SM, Waldmann TA, Wilson WH.

Leuk Lymphoma. 2018 Jun;59(6):1466-1469. doi: 10.1080/10428194.2017.1387908. Epub 2017 Oct 16. No abstract available.

24.

IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56bright NK Cells and Increases NK-Cell Cytokine Release Capabilities.

Dubois S, Conlon KC, Müller JR, Hsu-Albert J, Beltran N, Bryant BR, Waldmann TA.

Cancer Immunol Res. 2017 Oct;5(10):929-938. doi: 10.1158/2326-6066.CIR-17-0279. Epub 2017 Aug 25.

25.

Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.

Perera LP, Zhang M, Nakagawa M, Petrus MN, Maeda M, Kadin ME, Waldmann TA, Perera PY.

Am J Hematol. 2017 Sep;92(9):892-901. doi: 10.1002/ajh.24794. Epub 2017 Jun 5.

26.

Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.

Chen J, Zhang Y, Petrus MN, Xiao W, Nicolae A, Raffeld M, Pittaluga S, Bamford RN, Nakagawa M, Ouyang ST, Epstein AL, Kadin ME, Del Mistro A, Woessner R, Jaffe ES, Waldmann TA.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3975-3980. doi: 10.1073/pnas.1700682114. Epub 2017 Mar 29.

27.

JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.

Waldmann TA.

Mol Cell Endocrinol. 2017 Aug 15;451:66-70. doi: 10.1016/j.mce.2017.02.019. Epub 2017 Feb 15. Review.

28.

Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.

Waldmann TA, Chen J.

Annu Rev Immunol. 2017 Apr 26;35:533-550. doi: 10.1146/annurev-immunol-110416-120628. Epub 2017 Feb 9. Review.

PMID:
28182501
29.

Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.

Sharma K, Janik JE, O'Mahony D, Stewart D, Pittaluga S, Stetler-Stevenson M, Jaffe ES, Raffeld M, Fleisher TA, Lee CC, Steinberg SM, Waldmann TA, Morris JC.

Clin Cancer Res. 2017 Jan 1;23(1):35-42. doi: 10.1158/1078-0432.CCR-16-1022. Epub 2016 Aug 2.

30.

MHC I Expression Regulates Co-clustering and Mobility of Interleukin-2 and -15 Receptors in T Cells.

Mocsár G, Volkó J, Rönnlund D, Widengren J, Nagy P, Szöllősi J, Tóth K, Goldman CK, Damjanovich S, Waldmann TA, Bodnár A, Vámosi G.

Biophys J. 2016 Jul 12;111(1):100-12. doi: 10.1016/j.bpj.2016.05.044.

31.

Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2.

Hodson DJ, Shaffer AL, Xiao W, Wright GW, Schmitz R, Phelan JD, Yang Y, Webster DE, Rui L, Kohlhammer H, Nakagawa M, Waldmann TA, Staudt LM.

Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):E2039-46. doi: 10.1073/pnas.1600557113. Epub 2016 Mar 18.

32.

Erratum to: 'Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia'.

Yeh CH, Bai XT, Moles R, Ratner L, Waldmann TA, Watanabe T, Nicot C.

Mol Cancer. 2016 Mar 2;15:20. doi: 10.1186/s12943-016-0504-8. No abstract available.

33.

Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia.

Yeh CH, Bai XT, Moles R, Ratner L, Waldmann TA, Watanabe T, Nicot C.

Mol Cancer. 2016 Feb 16;15:15. doi: 10.1186/s12943-016-0500-z. Erratum in: Mol Cancer. 2016;15:20. Toshiki, Watanabe [Corrected to Watanabe, Toshiki].

34.

Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.

Ju W, Zhang M, Wilson KM, Petrus MN, Bamford RN, Zhang X, Guha R, Ferrer M, Thomas CJ, Waldmann TA.

Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):1624-9. doi: 10.1073/pnas.1524668113. Epub 2016 Jan 25.

35.

IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy.

Pilipow K, Roberto A, Roederer M, Waldmann TA, Mavilio D, Lugli E.

Cancer Res. 2015 Dec 15;75(24):5187-5193. doi: 10.1158/0008-5472.CAN-15-1498. Epub 2015 Dec 1. Review.

36.

Interleukin-15 Constrains Mucosal T Helper 17 Cell Generation: Influence of Mononuclear Phagocytes.

Yu H, Sui Y, Wang Y, Sato N, Frey B, Xia Z, Waldmann TA, Berzofsky J.

PLoS One. 2015 Nov 23;10(11):e0143001. doi: 10.1371/journal.pone.0143001. eCollection 2015.

37.

Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein.

Parra M, Liu X, Derrick SC, Yang A, Molina-Cruz A, Barillas-Mury C, Zheng H, Thao Pham P, Sedegah M, Belmonte A, Litilit DD, Waldmann TA, Kumar S, Morris SL, Perera LP.

PLoS One. 2015 Oct 27;10(10):e0141141. doi: 10.1371/journal.pone.0141141. eCollection 2015.

38.

Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).

Yokoyama S, Perera PY, Terawaki S, Watanabe N, Kaminuma O, Waldmann TA, Hiroi T, Perera LP.

J Clin Immunol. 2015 Oct;35(7):661-7. doi: 10.1007/s10875-015-0203-z. Epub 2015 Oct 9.

PMID:
26453583
39.

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

Janik JE, Morris JC, O'Mahony D, Pittaluga S, Jaffe ES, Redon CE, Bonner WM, Brechbiel MW, Paik CH, Whatley M, Chen C, Lee JH, Fleisher TA, Brown M, White JD, Stewart DM, Fioravanti S, Lee CC, Goldman CK, Bryant BR, Junghans RP, Carrasquillo JA, Worthy T, Corcoran E, Conlon KC, Waldmann TA.

Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13045-50. doi: 10.1073/pnas.1516107112. Epub 2015 Oct 5.

40.

Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.

Zhang M, Mathews Griner LA, Ju W, Duveau DY, Guha R, Petrus MN, Wen B, Maeda M, Shinn P, Ferrer M, Conlon KD, Bamford RN, O'Shea JJ, Thomas CJ, Waldmann TA.

Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12480-5. doi: 10.1073/pnas.1516208112. Epub 2015 Sep 22.

41.

IL-21-driven neoplasms in SJL mice mimic some key features of human angioimmunoblastic T-cell lymphoma.

Jain S, Chen J, Nicolae A, Wang H, Shin DM, Adkins EB, Sproule TJ, Leeth CM, Sakai T, Kovalchuk AL, Raffeld M, Ward JM, Rehg JE, Waldmann TA, Jaffe ES, Roopenian DC, Morse HC 3rd.

Am J Pathol. 2015 Nov;185(11):3102-14. doi: 10.1016/j.ajpath.2015.07.021. Epub 2015 Sep 9.

42.

Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.

Kreitman RJ, Stetler-Stevenson M, Jaffe ES, Conlon KC, Steinberg SM, Wilson W, Waldmann TA, Pastan I.

Clin Cancer Res. 2016 Jan 15;22(2):310-8. doi: 10.1158/1078-0432.CCR-15-1412. Epub 2015 Sep 8.

43.

Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.

Mitra S, Ring AM, Amarnath S, Spangler JB, Li P, Ju W, Fischer S, Oh J, Spolski R, Weiskopf K, Kohrt H, Foley JE, Rajagopalan S, Long EO, Fowler DH, Waldmann TA, Garcia KC, Leonard WJ.

Immunity. 2015 May 19;42(5):826-38. doi: 10.1016/j.immuni.2015.04.018.

44.

Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency.

Zhang Y, Tian S, Liu Z, Zhang J, Zhang M, Bosenberg MW, Kedl RM, Waldmann TA, Storkus WJ, Falo LD Jr, You Z.

Oncoimmunology. 2014 Dec 15;3(10):e959321. eCollection 2014 Nov.

45.
46.

miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.

Ji Y, Wrzesinski C, Yu Z, Hu J, Gautam S, Hawk NV, Telford WG, Palmer DC, Franco Z, Sukumar M, Roychoudhuri R, Clever D, Klebanoff CA, Surh CD, Waldmann TA, Restifo NP, Gattinoni L.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):476-81. doi: 10.1073/pnas.1422916112. Epub 2014 Dec 29.

47.

Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma.

Nakagawa M, Schmitz R, Xiao W, Goldman CK, Xu W, Yang Y, Yu X, Waldmann TA, Staudt LM.

J Exp Med. 2014 Dec 15;211(13):2497-505. doi: 10.1084/jem.20140987. Epub 2014 Dec 8.

48.

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, Chen J, Worthy TA, Figg WD Sr, Peer CJ, Sneller MC, Lane HC, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA.

J Clin Oncol. 2015 Jan 1;33(1):74-82. doi: 10.1200/JCO.2014.57.3329. Epub 2014 Nov 17.

49.

Interleukin-15 in the treatment of cancer.

Waldmann TA.

Expert Rev Clin Immunol. 2014 Dec;10(12):1689-701. doi: 10.1586/1744666X.2014.973856. Epub 2014 Oct 31. Review.

PMID:
25359408
50.

Distinct spatial relationship of the interleukin-9 receptor with interleukin-2 receptor and major histocompatibility complex glycoproteins in human T lymphoma cells.

Nizsalóczki E, Csomós I, Nagy P, Fazekas Z, Goldman CK, Waldmann TA, Damjanovich S, Vámosi G, Mátyus L, Bodnár A.

Chemphyschem. 2014 Dec 15;15(18):3969-78. doi: 10.1002/cphc.201402501. Epub 2014 Oct 8.

Supplemental Content

Loading ...
Support Center